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washed three times with HBSS containing 0.5mg/mL heparin sulfate,
detached with accutase, and resuspended in growth media for analysis.
Cell-associated ﬂuorescence was measured via ﬂow cytometry. Live cells
were discriminated via forward and side scatter; cell association was
quantiﬁed using the mean ﬂuorescence intensity (MFI). At each dosage,
MFI values between control and TAT-peptides were compared using
paired t-tests with an a priori signiﬁcance level of 0.05.
Results: The TAT-PTD resulted in signiﬁcantly more cell-associated
ﬂuorescence than the control peptide in a dose-dependent manner
implying that intracellular uptake was facilitated. The MFI values
for TAT-Treated cells (MFI: 313±61, 686±136, 2430±271 for peptide
concentrations of 1.25, 2.5, and 5mM, respectively) were signiﬁcantly
greater than those (110±15, 156±25, 280±36 for 1.25, 2.5, and 5mM,
respectively) for the chondrocytes treated with the control peptide (all
p ≤ 0.02). Cell association of TAT peptides was observed in various types
of chondrocytes from both male and female donors, from donors ranging
in age from 24 to 64, and from normal and OA donors.
Conclusions: These data suggest that the TAT protein transduction
domain facilitates peptide-uptake in primary human chondrocytes from
diverse donor populations with varying age and OA grades. Future studies
will determine whether the TAT PTD can be used to deliver therapeutic
molecules to in vivo articular cartilage for modulating chondrocyte
behavior toward treating osteoarthritis.
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Purpose: Traditional medicine has widely been used Phellodendron
amurense Rupr. (Rutaceae) to treat various inﬂammatory diseases
including arthritis. In this study, we investigated the effects of
Phellodendron amurense (P. amurense) in protecting cartilage, including
regulating the levels of aggrecanases, matrix metalloproteinases
(MMPs)/tissue inhibitor of metalloproteinase (TIMP), proinﬂammatory
cytokines and signaling of the mitogen activated protein kinase (MAPK)
pathway in human osteoarticular cartilage and chondrocytes.
Methods: Explants from human osteoarthritis cartilage were cultured
alone or in IL-1a for 7 days with or without P. amurense ethanol
extract or celecoxib (40, 100, 200mg/ml). The effect of P. amurense on
matrix degradation induced by IL-1a in human articular cartilage was
assessed by staining, and the quantities of sulfated glycosaminoglycan
(GAG) and type II collagen were calculated from the culture media.
The levels of aggrecanases, MMPs, TIMP, and PGE2 in the culture
media were investigated using an enzyme-linked immunosorbent assay
(ELISA). In addition, reverse transcription polymerase chain reaction (RT-
PCR) evaluated the mRNA expression of aggrecanases, MMPs and TIMP.
Furthermore, Western blot analysis was performed to identify the roles
that P. amurense played in the ERK, JNK and p38 signaling pathways.
Results: P. amurense showed no evident cytotoxicity on human
articular cartilage. P. amurense signiﬁcantly inhibited the IL-1a-induced
degradation of GAG and type II collagen from human osteoarticular
cartilage in a concentration-dependent manner. Celecoxib did not
signiﬁcantly inhibit IL-1a-induced release of GAG and only slightly
reduced type II collagen. P. amurense also dose-dependently decreased
the levels of aggrecanase-1 and -2, MMP-1, -3, and -13, whereas it
increased TIMP-1 expression in human osteoarticular cartilage. Celecoxib
only decreased MMP-1 and MMP-13 levels in human osteoarticular
cartilage. In addition, P. amurense reduced the phosphorylation of
extracellular signal regulated kinase (ERK)1/2, Jun NH2-terminal kinase
(JNK) and activated phospho-p38 MAPK in a dose-dependent manner in
human osteoarthritic chondrocytes.
Conclusions: P. amurense inhibited osteoarticular cartilage and
chondrocyte destruction by inhibiting proteoglycan release and type
II collagen degradation, down-regulating aggrecanases, MMP activities
and phospho-ERK1/2, JNK and p38 MAP kinase signalling, and up-
regulating TIMP-1 activity. Therefore, our results suggest that P. amurense
is a potential therapeutic agent to protection cartilage against OA
progression.
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Purpose: To evaluate the patterns of therapy switching, add-on and
discontinuation after initiation of treatment with select currently
recommended treatments in patients with OA.
Methods: Using the United Kingdom THIN (The Health Improvement
Network) database, patients at least 18 years of age, with at
least two healthcare encounters with an associated diagnosis of
OA starting January 1, 2005, with the two diagnoses being at
least 30 days apart, newly prescribed (index event) non-selective
nonsteroidal anti-inﬂammatory drugs (NS-NSAIDs, N =6,639; average age
± SD, 67.2±11.4 years), Cyclooxygenase-2 inhibitors (Cox-2s, N =542;
68.0±11.2 years), acetaminophen (N=3,215; 74.1±10.1 years), tramadol
(N=1,724; 70.1±11.2 years), weak opioids (N=5,886; 70.4±11.1 years)
and strong opioids (N=178; 74.0±11.3 years) within 30 days prior,
or anytime after the ﬁrst diagnosis of OA were selected. Descriptive
statistics, Kaplan Meier analyses, and COX proportional hazards model
were used to evaluate patterns of therapy switching, add-on, and discon-
tinuation during the 12-months post-index period. The study protocol
was approved by the Cambridgeshire 4 Research Ethics Committee.
Results: Substantial proportions of OA patients switched therapy within
a year after treatment initiation and rates of therapy switching were
signiﬁcantly different (p < 0.0001) across the evaluated drugs groups: NS-
NSAIDs, 30.0%; Cox-2s, 44.6%; acetaminophen, 32.8%; tramadol, 57.8%;
weak opioids, 33.7%; and strong opioids, 59.6%. Patterns of therapy
add-on at 12-months were also signiﬁcantly (p < 0.0001) different,
although rates of therapy add-on were much lower: NS-NSAIDs, 9.1%;
Cox-2s, 13.5%; acetaminophen, 9.1%; tramadol 11.8%; weak opioids,
8.7%; and strong opioids, 15.2%. A majority of patients in each group
discontinued therapy during the 12-months post-index period (91.9%,
86.9%, 91.4%, 89.7%, 93.2%, and 84.3% of patients in the NS-NSAIDs, Cox-
2s, acetaminophen, tramadol, weak opioids and strong opioids groups,
respectively). An evaluation of estimated probabilities suggested that
over two thirds of patients who switched, augmented or discontinued
therapy did so within the ﬁrst 2-months, and a majority did so within
6-months of treatment initiation.
Conclusions: Results of this study suggest that therapy switching
and discontinuation were very common among OA patients initiating
treatment with the currently recommended medication classes for
this painful condition. The observed high rates of therapy switching
and discontinuation may be indicative of inadequate pain relief or
potentially intolerable side-effects of therapies. Given the human and
economic burden of OA, future research may beneﬁt from a focus
on comparative efﬁcacy and safety parameters to further differentiate
treatment options.
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Purpose: Osteoarthritis is a multifactorial disease characterized by
loss of articular cartilage and subchondral plate thickening. Therefore,
